Abstract
Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have